Fungal Infections – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides a comprehensive overview of the fungal infections clinical trials landscape. It provides top-line data relating to the clinical trials on fungal infections including an overview of trials count and their average enrollment in top countries conducted globally. The report also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).
The fungal Infections clinical trial report consists of 1851 trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0. Out of 1327 completed trials, 708 trials have achieved end point(s). The number of fungal infections clinical trials conducted globally, has increased by 23% for the period 2016-2020. The average number of patients enrolled was highest in the year 2016. As of December 2021, more than 50% of trials have been sponsored by companies and more than 40% by institutions. The rest were sponsored by the Government.
What are the top regions and countries in the fungal infections clinical trials market?
In total there were 1,851 clinical trials conducted on fungal infections. Out of these, more than 30% were conducted in Asia-Pacific. It was followed by North America and Europe at more than 25% each. The Middle East and Africa covered about 10% of the clinical trials and the lowest was South and Central America. In the Asia-Pacific region, China has the highest number of fungal infection clinical trials accounting for more than 35% of the total trials in the region. The US makes up nearly 80% of the total clinical trials in North America. The rest is made up of Canada and Mexico. Among the European countries, Germany has the highest number of fungal infections clinical trials accounting for more than 110 trials. Iran has the highest number of clinical trials in the Middle East and Africa and Brazil accounts for the greatest number of trials in South and Central America.
In a country-wise analysis, The US has the highest number of fungal infections clinical trials followed by China and India. France has the highest average patient enrollment and China has the greatest number of clinical trials in progress. China is closely followed by the US in this respect. Other top countries include Germany, Iran, Canada, France, Spain, the UK, and Russia.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, there were 922 clinical trials conducted as of December 2021. Of these, the US has the highest number of clinical trials while Germany has the highest proportion of fungal infections to infectious disease clinical trials. There were 60 clinical trials in progress and 563 trials are completed. The trials that are terminated/ suspended or withdrawn accounted to 89. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, there was a total of 561 clinical trials being conducted. Of these, China has the highest number of clinical trials and India has the highest proportion of fungal infections in infectious disease clinical trials. As of December 2021, there were 69 clinical trials in progress and 295 trials were completed. The trials that were terminated/ suspended or withdrawn accounted for 68. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
Fungal infections clinical trials market, by regions
For more regional insights, download a free report sample
What are the phases in the fungal infections clinical trials market?
As of December 2021, there were 540 clinical trials in phase II, of which 58 clinical trials were in progress for the time period of 1995-2021. This was followed by the greatest number of clinical trials in phase I. phase III and phase IV accounted for an equal percentage of clinical trials in the market. As of December 2021, phase II had the maximum number of clinical trials in progress accounting for more than 30% of the trials. There were 184 clinical trials in progress and 1,327 trials were completed. The trials that were terminated/suspended or withdrawn accounted to 223. This was due to the lack of efficacy, safety, and lack of accrual of subjects. Out of more than 1,300 completed trials, a little less than 85% reached end points.
Which are the key players in the fungal infections clinical trials market?
The key players in the fungal infections clinical trials market are Pfizer Inc, Merck & Co Inc, Astellas Pharma Inc, Scynexis Inc, Basilea Pharmaceutica Ltd, GlaxoSmithKline Plc, Novartis AG, F2G Ltd, Bausch Health Companies Inc, and Johnson & Johnson. Pfizer Inc sponsored the highest number of fungal infections clinical trials followed by Merck & Co Inc and Astellas Pharma Inc.
Fungal infections clinical trials market, by key players
To know more about key players, download a free report sample
Market report scope
Key regions | Asia-Pacific, Northern America, Europe, Middle East and Africa, and South and Central America |
Key countries | The US, China, India, Germany, Iran, Canada, France, Spain, United Kingdom, and Russia |
Key companies | Pfizer Inc, Merck & Co Inc, Astellas Pharma Inc, Scynexis Inc, Basilea Pharmaceutica Ltd, GlaxoSmithKline Plc, Novartis AG, F2G Ltd, Bausch Health Companies Inc, and Johnson & Johnson |
The report provides an in-depth analysis of:
- A snapshot of the global clinical trials landscape
- Top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end point status
- Top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- All the unaccomplished trials (terminated, suspended and withdrawn) with reason for unaccomplishment
- Enrollment trends for the past five years
- Latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level
Merck & Co Inc
Astellas Pharma Inc
Scynexis Inc
Basilea Pharmaceutica Ltd
GlaxoSmithKline Plc
Novartis AG
F2G Ltd
Bausch Health Companies Inc
Johnson & Johnson
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key regions in the fungal infections clinical trials market?
The key regions in the fungal infections clinical trials market are Asia-Pacific, Northern America, Europe, Middle East & Africa, and South and Central America.
-
What are the key countries in the fungal infections clinical trials market?
Key countries in the fungal infections clinical trials market are the US, China, India, Germany, Iran, Canada, France, Spain, the UK, and Russia.
-
Which are the key companies in the fungal infections clinical trials market?
Key companies in the fungal infections clinical trials market are Pfizer Inc, Merck & Co Inc, Astellas Pharma Inc, Scynexis Inc, Basilea Pharmaceutica Ltd, GlaxoSmithKline Plc, Novartis AG, F2G Ltd, Bausch Health Companies Inc, and Johnson & Johnson.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.